https://qima-lifesciences.com/wp-content/uploads/2023/10/mw_vitiligo.png 368 655 Julie https://qima-lifesciences.com/wp-content/uploads/2021/10/QIMA_life_sciences@4x1.png Julie2023-08-24 11:36:442023-10-31 11:37:23Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm
Facial repigmentation is the primary outcome measure for most vitiligo trials. The Facial Vitiligo Area Scoring Index (F-VASI) score is often chosen as the primary outcome measure to assess the efficacy of treatments for facial vitiligo.
https://qima-lifesciences.com/wp-content/uploads/2020/06/mw_Type-1-cytokines.jpg 368 655 Julie https://qima-lifesciences.com/wp-content/uploads/2021/10/QIMA_life_sciences@4x1.png Julie2020-06-04 15:12:052020-06-09 15:13:30Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo
Loss of melanocytes is the pathological hallmark of vitiligo.
https://qima-lifesciences.com/wp-content/uploads/2016/05/mw_Cystinosin-is-a-melanosomal-protein.jpg 368 655 Guillaume https://qima-lifesciences.com/wp-content/uploads/2021/10/QIMA_life_sciences@4x1.png Guillaume2012-05-14 09:05:322019-05-31 15:06:05Cystinosin is a melanosomal protein that regulates melanin synthesis
In vitro studies showed that cystinosin was located at melanosomes. CTNS silencing led to a 75% reduction of melanin synthesis that was caused by a degradation of tyrosinase by lysosomal proteases. Our results objectify the pigmentation defect in patients with cystinosis. We also identify the role of CTNS in melanogenesis and add a new gene to the list of the genes involved in the control of skin and hair pigmentation.